We report a case of a patient affected by severe eosinophilic asthma with nasal polyps (SEA+NP) who developed coronavirus disease 2019 (COVID-19) six months after starting benralizumab as add-on therapy. Both SEA and NP were under control with no exacerbations at the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The patient was hospitalized for four months, during which the treatment with benralizumab was interrupted. Despite the onset of bilateral interstitial pneumonia, developed as a consequence of the SARS-CoV-2 infection, the patient was discharged without complications, with a significant improvement in the chest CT scan following the administration of systemic corticosteroids (SCS) and low-flow oxygen therapy. The treatment with benralizumab was reintroduced at the regular dosing regimen immediately after his discharge. Lung function was assessed three months after the discharge and showed normal levels as before the development of COVID-19 symptoms. A long-term follow-up after 26 months from the introduction of benralizumab showed a normal lung function and well-controlled asthma, without exacerbations or the need for corticosteroid bursts.
【저자키워드】 emergency medical service, long term follow up, "anti il5-r", emergency visit|||spirometry|||biologic|||long term follow up, covid-19|||severe eosinophilic asthma|||nasal polyps|||benralizumab|||interstitial pneumonia, 【초록키워드】 Corticosteroid, Treatment, coronavirus disease, SARS-CoV-2, Asthma, coronavirus, therapy, Hospitalized, Infection, nasal, discharge, Chest, Lung function, Patient, complications, interstitial pneumonia, COVID-19 symptoms, administration, Long-term follow-up, regimen, acute respiratory syndrome, bursts, affected, the patient, discharged, low-flow oxygen therapy, SCS, SEA, systemic corticosteroid, the SARS-CoV-2, 【제목키워드】 SARS-CoV-2, report, while, Eosinophilic, Polyposis,